The Use of PARP Inhibitors in Breast Cancer: Challenges - PowerPoint Presentation

calandra-battersby . @calandra-battersby

404 views
Uploaded On 2018-09-25

The Use of PARP Inhibitors in Breast Cancer: Challenges - PPT Presentation

and Opportunities This program will include a discussion of offlabel treatment and investigational agents not approved by the FDA for use in the United States and data that were presented in abstract form These data should be considered preliminary until published in a peerreviewed journal ID: 679955

parp study data cancer study parp cancer data breast cont olympiad abbreviations talazoparib inhibitors olympia design aes brocade brightness

Link:

Copy

Embed:

<iframe width="560" height="315" src="https://www.docslides.com/embed/679955" frameborder="0" allowfullscreen></iframe>

Download Presentation from below link

Download Presentation The PPT/PDF document "The Use of PARP Inhibitors in Breast Can..." is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.

Presentation Transcript

Slide1

The Use of PARP Inhibitors in Breast Cancer: Challenges and OpportunitiesSlide2
Slide3

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use

in the United States and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.Slide4

PARP and PARP InhibitionSlide5

PARP Inhibitors Studied in Breast CancerSlide6

BROCADE 2: Study DesignSlide7

BROCADE 2: ResultsSlide8

I-SPY2: Veliparib/Carboplatin GraduatesSlide9

BrighTNess: TNBC and Continuous DosingSlide10

BrighTNess Efficacy DataSlide11

Phase 2 Studies of Olaparib in gBRCA+ MBCSlide12

ABRAZO: Talazoparib Phase 2 in gBRCA+ MBCSlide13

OlympiAD Study DesignSlide14

Primary Endpoint: PFS by BICRSlide15

Time to Second Progression or Death (PFS2) by Investigator AssessmentSlide16